December 2019 Price Concessions – 1st update

THIS CONTENT HAS NOW EXPIRED

December 2019 Price Concessions – 1st update

December 13, 2019

Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions:

Drug Pack size Price Concession
Co-careldopa 25mg/100mg tablets 100 £10.99
Cyclizine 50mg/1ml solution for injection ampoules 5 £11.98
Desmopressin 200microgram tablets 30 £19.85
Dexamfetamine 5mg/5ml oral solution sugar free 500ml £381.63
Indapamide 2.5mg tablets 28 £2.50
Irbesartan 300mg tablets 28 £6.93
Irbesartan 75mg tablets 28 £4.06
Levetiracetam 250mg tablets 60 £5.75
Levetiracetam 500mg tablets 60 £9.92
Levetiracetam 1g tablets 60 £10.99
Memantine 10mg tablets 28 £4.00
Memantine 20mg tablets 28 £8.86
Mirtazapine 15mg tablets 28 £2.61
Mirtazapine 45mg tablets 28 £4.49
Mometasone 50micrograms/dose nasal spray 140 dose £4.42
Nefopam 30mg tablets 90 £19.79
Nifedipine 5mg capsules 90 £51.95
Nifedipne 10mg capsules 90 £65.63
Nifedipine 10mg modified release tablets 56 £9.23
Quetiapine 25mg tablets 60 £2.70
Ranitidine 300mg tablets 30 £4.95
Tizanidine 2mg tablets 120 £12.00

No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated December 2019 Drug Tariff price. Contractors will be alerted to further updates to the price concession list through our website and via our e-news email.  If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.

If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.
Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and if appropriate discuss the issue with DHSC.



Posted in:


More Latest News >

Wuhan Novel Coronavirus

The Medicines & Healthcare products Regulatory Agency (MHRA) has via its Central Alerting System (CAS) published an alert regarding the...